RxDoctor Payments Data

Saman Ghalili, MD

General Practice · El Segundo, CANPI 1891724993

Payments from drug & device makers

$893in general payments, 2019–2025

Across 46 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$166
  • GSK$165
  • Merck$132
  • Amgen$109
  • Lilly USA, LLC$81
  • Sanofi Pasteur Inc.$60
  • plus $180 from 7 others

What the payments were for

  • Food & beverage$87398%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie10$166
GSK6$165
Merck6$132
Amgen5$109
Lilly USA, LLC3$81
Sanofi Pasteur Inc.3$60
Pfizer2$47
Takeda Pharmaceuticals U.S.A., Inc.6$40
Organon1$24
Cipher Pharmaceuticals US LLC1$21
Dexcom, Inc.1$18
Gilead1$17
Boston Scientific1$13

How this compares

$893 in reported general payments places this provider in the 75th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$10,059
Medicare patients
46
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate45$68,376
OzempicSemaglutide36$31,782
Qvar RedihalerBeclomethasone Dipropionate17$4,430
Atorvastatin Calcium284$3,941
Albuterol Sulfate HfaAlbuterol Sulfate71$2,448
Meloxicam130$2,405
Omeprazole195$2,122
Tamsulosin Hcl82$1,995
Fluticasone Propionate135$1,677
Glipizide-MetforminGlipizide/Metformin Hcl26$1,496
Alendronate Sodium116$1,418
Metformin Hcl144$1,364
Escitalopram Oxalate58$1,336
Benazepril Hcl96$1,041
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$132$68,37645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 12,963 general practice providers in California.

Other general practice in El Segundo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →